Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

104
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
104
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

95
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
95
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

97
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
97
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

82
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
82
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

2.5K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
2.5K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

85
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
85

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Primary aortic coarctation repair in adolescents and adults.

JTCVS structural and endovascular·2026
Same author

Open, hybrid, and endovascular repair of recoarctation, aneurysm, and pseudoaneurysm after aortic coarctation repair.

JTCVS techniques·2026
Same author

Dual-Phase Increase in Atrial Arrhythmia Prevalence Following Percutaneous Atrial Septal Defect Closure.

Journal of the Society for Cardiovascular Angiography & Interventions·2025
Same author

Multimodal Imaging to Guide Stent Placement in a Patient After Fontan Palliation With Restrictive Interatrial Communication.

JACC. Case reports·2025
Same author

Biventricular Fontan conversion in criss-cross, superior-inferior ventricles using arterial switch and extra-anatomical left ventricle to aorta prosthesis.

JTCVS techniques·2025
Same author

Pediatric and Congenital Cardiac Services: An Innovative and Empowering Approach to Global Training and Equitable Care.

Journal of the American Heart Association·2025

相关实验视频

Updated: May 9, 2025

A Rodent Model of The Ross Operation: Syngeneic Pulmonary Artery Graft Implantation in A Systemic Position
11:20

A Rodent Model of The Ross Operation: Syngeneic Pulmonary Artery Graft Implantation in A Systemic Position

Published on: April 1, 2022

3.0K

肺静脉狭窄:对未来的乐观看法

Patcharapong Suntharos1, Marin Satawiriya2, Lourdes R Prieto3

  • 1Cleveland Clinic Children's Hospital, Cleveland, Ohio.

Current opinion in cardiology
|April 30, 2025
PubMed
概括

肺静脉狭窄症 (PVS) 治疗的进步,包括西罗和手术技术,改善了生存率. 频繁的重新干预是控制这种罕见疾病和保持静脉通透性的关键.

关键词:
毒品排放气球可以释放毒品.药物释放的支架可以释放药物.肺静脉狭窄症 肺静脉狭窄症 肺静脉狭窄症静止性静止症是一种静止症.这是西洛利斯 ( sirolimus).

更多相关视频

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats
07:41

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats

Published on: March 1, 2022

2.8K
Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat
08:34

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat

Published on: November 18, 2018

7.1K

相关实验视频

Last Updated: May 9, 2025

A Rodent Model of The Ross Operation: Syngeneic Pulmonary Artery Graft Implantation in A Systemic Position
11:20

A Rodent Model of The Ross Operation: Syngeneic Pulmonary Artery Graft Implantation in A Systemic Position

Published on: April 1, 2022

3.0K
A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats
07:41

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats

Published on: March 1, 2022

2.8K
Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat
08:34

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat

Published on: November 18, 2018

7.1K

科学领域:

  • 心脏病学 心脏病学
  • 肺部医学 肺部医学
  • 儿童心脏病学 儿童心脏病学

背景情况:

  • 肺静脉狭窄 (PVS) 是一种罕见的疾病,具有显著的发病率和死亡率.
  • 在PVS中预防复仍然是一个关键的临床挑战.

研究的目的:

  • 审查肺静脉狭窄症最近的治疗进展.
  • 突出显示PVS患者生存益处的疗法.

主要方法:

  • 对儿科和成人PVS的当前干预和手术策略的审查.
  • 对新型抑制剂和外科手术技术的分析.
  • 检查频繁的再干预和协作护理的作用.

主要成果:

  • 儿科PVS的透导管和手术干预具有较高的复缩率,但通过频繁的重新干预来维持静脉通透性可以改善结果.
  • 局部和全身 sirolimus 输送显示在减少复原和重新干预方面有希望,改善生存率.
  • 新的外科手术方法和混合技术提供了生存的好处.
  • 成人发病的PVS虽然很少见,但通常会对过导管干预做出反应.

结论:

  • 频繁重新干预的积极战略对于管理PVS至关重要.
  • 对PVS机制的更好理解推动了新的多方疗法,从而提高了生存率.
  • 多专业团队和协作研究对于推进PVS护理至关重要.